Digital health, built and validated.

Ventures that reach the clinic

Dr. Damon Tojjar co-develops and leads digital health products that are clinically grounded and validated in the real world. Two define the work: EASY Diabetes and Vi-Health.

See the venturesAbout
  • Medtech4HealthInnovation Award
  • RCTEASY-1, registered trial
  • EITTop 20 Deep Tech
  • Numanacquired Vi-Health

Selected work

From discovery to deployment.

  1. EASY Diabetes

    Co-developer and Head of Medical and Science

    An AI-based clinical decision-support system for type 2 diabetes, developed with patients, clinicians, and researchers. Its randomized controlled trial, EASY-1 (NCT03258268), compared the system against standard of care. EASY Diabetes received the Medtech4Health Innovation Award.

  2. Vi-Health

    Co-founder and Managing Director

    A digital health company offering an AI symptom checker and e-consultation tools. Vi-Health was selected as one of 20 finalists (Top 20 Deep Tech) in the European Institute of Innovation and Technology's EIT Digital Challenge and was later acquired by Numan.

  3. Novo Nordisk, Global Development

    International Medical Manager and Principal Medical Specialist

    Helped lead global clinical programs for GLP-1, insulin, and combination therapies, including Tresiba, Ryzodeg, and Xultophy, keeping the clinical evidence solid while the work ran across many countries.

About the builder

A clinician who ships.

Dr. Damon Tojjar is a physician-scientist and digital health entrepreneur whose work spans global drug development, clinical AI, and medical-device regulation, with research roots in diabetes genetics and metabolic disease. Trained in medicine at Lund University and in systems medicine at Stanford, his diabetes-genetics research includes a shared (co-second) author contribution to a paper in Science, recognized with the Magnus Blix Award, and a Diabetes Care meta-analysis cited more than 800 times. He co-developed EASY Diabetes, an AI decision-support system that won Sweden's Medtech4Health Innovation Award, and co-founded Vi-Health, which was selected as one of 20 finalists (Top 20 Deep Tech) in the EIT Digital Challenge and later acquired by Numan.

Beyond his own ventures, he mentors early-career founders and scientists, including with UCLA Ventures and the Nucleate biotech program, and has served as a board member of Lund University's innovation and holding companies, LU Innovation (now LU Ventures) and LU Holding.

Frequently asked

About the ventures.

What is EASY Diabetes?

An AI-based clinical decision-support system for type 2 diabetes, co-developed and led by Dr. Tojjar. Its EASY-1 randomized controlled trial (NCT03258268) compared the system against standard of care. It received the Medtech4Health Innovation Award.

What was Vi-Health?

A digital health company with an AI symptom checker and e-consultation tools, co-founded by Dr. Tojjar. It was selected as one of 20 finalists (Top 20 Deep Tech) in the EIT Digital Challenge and later acquired by Numan.

Contact

Get in touch.

For partnership, advisory, or investment conversations, reach out directly.

contact@tojjarlabs.com